Ratings Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Delayed Hong Kong S.E. Other stock markets 11:59:41 2024-06-11 pm EDT			5-day change	1st Jan Change
15.62 ^HKD	-1.76%		+5.68%	-27.35%

Jun. 04	Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	MT
May. 24	Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 3.71 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ZAI LAB LIMITED	-27.35%	1.98B	-
CSL LIMITED	-1.46%	92.26B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-2.63%	38.11B	A-
BIOGEN INC.	-12.76%	32.9B	B-
UCB	+66.54%	26.51B	A
BIOMARIN PHARMACEUTICAL INC.	-13.02%	15.75B	C
INCYTE CORPORATION	-5.27%	13.36B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.50%	11.65B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.11%	10.12B	B
ALTEOGEN INC.	+187.82%	9.78B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes